These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 29433840)

  • 1. Thrombotic microangiopathy and accelerated hypertension after treatment with interferon beta.
    Pérez EP; Sánchez de la Nieta García MD; López LG; Hernández FR
    Nefrologia (Engl Ed); 2018; 38(5):564-565. PubMed ID: 29433840
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on thrombotic microangiopathy induced by interferon-β therapy.
    Cavoli GL; Passantino R; Tortorici C; Bono L; Ferrantelli A; Rotolo U
    Clin Nephrol; 2012 Dec; 78(6):506-7. PubMed ID: 23164420
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report.
    Broughton A; Cosyns JP; Jadoul M
    Clin Nephrol; 2011 Nov; 76(5):396-400. PubMed ID: 22000560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta in multiple sclerosis causing thrombotic microangiopathy.
    Yam C; Fok A; Mclean C; Butler E; Kempster P
    Intern Med J; 2019 Feb; 49(2):274-276. PubMed ID: 30754081
    [No Abstract]   [Full Text] [Related]  

  • 5. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.
    Mahe J; Meurette A; Moreau A; Vercel C; Jolliet P
    Drug Des Devel Ther; 2013; 7():723-8. PubMed ID: 23950639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic Microangiopathy Presenting with Intestinal Involvement Following Long-term Interferon-β1b Treatment for Multiple Sclerosis.
    Omoto S; Utsumi T; Matsuno H; Terasawa Y; Iguchi Y
    Intern Med; 2018 Mar; 57(5):741-744. PubMed ID: 29151517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.
    Gerischer LM; Siebert E; Janke O; Jungehuelsing GJ; Ruprecht K
    Mult Scler Relat Disord; 2016 Nov; 10():63-65. PubMed ID: 27919500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferon ß, nephrotic syndrome and thrombotic microangiopathy].
    Quintana LF; Campistol JM
    Med Clin (Barc); 2015 Jan; 144(2):65-6. PubMed ID: 25458512
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis.
    Mrabet S; Dahmane R; Raja B; Fradi A; Aicha NB; Sahtout W; Azzabi A; Guedri Y; Zellama D; Achour A; Sfar I; Goucha R; Abdessayed N; Mokni M
    Br J Clin Pharmacol; 2023 May; 89(5):1682-1685. PubMed ID: 36480744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic microangiopathy associated with interferon beta.
    Hunt D; Kavanagh D; Drummond I; Weller B; Bellamy C; Overell J; Evans S; Jackson A; Chandran S
    N Engl J Med; 2014 Mar; 370(13):1270-1. PubMed ID: 24670186
    [No Abstract]   [Full Text] [Related]  

  • 11. Antineoplastic agents and thrombotic microangiopathy.
    Garcia G; Atallah JP
    J Oncol Pharm Pract; 2017 Mar; 23(2):135-142. PubMed ID: 26854265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial hypertension induced by interferon beta 1b in a patient with multiple sclerosis.
    Modrego PJ; Gazulla J
    Mult Scler; 2012 Nov; 18(11):1655-6. PubMed ID: 22419671
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of progressive hypertension preceding gemcitabine-associated thrombotic microangiopathy complicated by acute kidney injury and stroke.
    Phelan PJ; Liew A; Magee C
    Ren Fail; 2009; 31(8):743-4. PubMed ID: 19814643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta related pulmonary arterial hypertension; an emerging worrying entity?
    Govern EM; Judge EP; Kavanagh E; Gaine S; Lynch T
    Mult Scler Relat Disord; 2015 May; 4(3):284-6. PubMed ID: 26008947
    [No Abstract]   [Full Text] [Related]  

  • 15. Case report of thrombotic microangiopathy associated with subcutaneous interferon beta-1a: an emerging complication?
    Azkune Calle I; Sánchez Menoyo JL; Ruiz Ojeda J; García Moncó JC; Etxeguren Urkixo I
    Neurologia; 2016 Sep; 31(7):508-9. PubMed ID: 25449964
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversible Interferon-Induced Pulmonary Arterial Hypertension in a Patient With Multiple Sclerosis.
    García Ortega A; López Reyes R; Torrents Vilar A; Zaldivar Olmeda E; Prado Barragan M
    Arch Bronconeumol; 2017 Oct; 53(10):596-597. PubMed ID: 28416206
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-associated thrombotic microangiopathies.
    Kreuter J; Winters JL
    Semin Thromb Hemost; 2012 Nov; 38(8):839-44. PubMed ID: 23037985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic microangiopathy complicating pegylated interferon treatment of hepatitis C infection.
    Iskander D; Wickremasinghe M; Bain BJ
    Am J Hematol; 2011 Oct; 86(10):859. PubMed ID: 21630311
    [No Abstract]   [Full Text] [Related]  

  • 19. Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review.
    Demerouti E; Karyofyllis P; Athanassopoulos G; Karatasakis G; Tsiapras D; Manginas A; Voudris V
    Mult Scler Relat Disord; 2019 Feb; 28():273-275. PubMed ID: 30639829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug induced thrombotic microangiopathy caused by levofloxacin.
    Kazi S; Preston GC
    J R Coll Physicians Edinb; 2018 Jun; 48(2):127-129. PubMed ID: 29992202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.